Host Cell Protein Testing Market Summary
As per MRFR Analysis, the Global Host Cell Protein Testing Market was valued at USD 1.31 billion in 2023 and is projected to reach USD 2.17 billion by 2032, growing at a CAGR of 5.77% from 2023 to 2032. The market growth is driven by increased R&D activities in the biopharmaceutical sector, technological advancements, and rising demand for protein-based vaccines. The ELISA-based assays segment held the largest market share in 2022, while biopharmaceutical companies are expected to be the fastest-growing end-user segment during the forecast period. North America dominated the market in 2022, attributed to a high number of clinical trials and innovative medicine demand.
Key Market Trends & Highlights
Key trends driving the Host Cell Protein Testing Market include advancements in R&D and increasing disease prevalence.
- Market size in 2023: USD 1.31 billion; projected to grow to USD 2.17 billion by 2032.
- CAGR of 5.77% during the forecast period (2023-2032).
- ELISA-based assays held the majority share in 2022 due to rising clinical trials.
- North America accounted for the largest market share in 2022, driven by clinical trials and innovative medicine.
Market Size & Forecast
2023 Market Size: USD 1.31 billion
2032 Market Size: USD 2.17 billion
CAGR: 5.77%
Largest Regional Market Share in 2022: North America.
Major Players
Key players include Enzo Life Sciences, Inc (US), Bio-Rad Laboratories, Inc (US), Biogenes GmbH (Germany), Cisbio Bioassays (France), and Thermo Fisher Scientific Inc (US).
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Host Cell Protein Testing Market Trends
- The Growing R&D Activities boost market growth.
The emergence of chronic and viral diseases around the world has increased expenditure on R&D initiatives. The drug development process is being accelerated by technological advancement and innovation in biomedical sciences. This advancement has accelerated the development of drugs and reduced the drug lifecycle period by 500 days. Additionally, educational institutions and research organizations are investing in the production of fused and functional proteins. The rising investments in pharmaceutical stability have increased the demand for better host cell protein methods. Moreover, Scientists are researching strategies to keep antibodies and proteins stable in biological environments.
Furthermore, the growing demand for protein-based vaccines to treat viral, bacterial, and other microbe-based diseases has fueled global research efforts. The rising prevalence of diseases such as paroxysmal nocturnal hemoglobinuria and factor VII and VIII deficiency has boosted research into enhanced medicinal and commercial protein manufacturing. Thus, during the forecast period, such opportunities are projected to drive the host cell protein testing market.
Host Cell Protein Testing Market Segment Insights
Host Cell Protein Testing Type Insights
The Host Cell Protein Testing Market segmentation, based on type, includes PCR-based assays, ELISA-based assays, mass spectrometry-based assays, and others. Mass spectrometry-based assays are further segmented into Liquid Chromatography–Mass Spectrometry (LC-MS), Tandem Mass Spectrometry (MS/MS), and others. The ELISA-based Assays segment held the majority share in 2022 in the Host Cell Protein Testing Market revenue. This is due to the increasing incidence of infectious diseases and the rising number of clinical trials of antibodies-based vaccines.
June 2023: Biogenes GmbH (Germany) launched the HEK293 HCP ELISA kit. The HEK 293 HCP ELISA Kit, can be used as a process development tool to monitor the best removal of host cell contaminants as well as in routine final product release testing.
Figure 2: HOST CELL PROTEIN TESTING MARKET SIZE, BY TYPE, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Host Cell Protein Testing End User Insights
The Host Cell Protein Testing Market segmentation is based on end user that include contract research organizations, biopharmaceutical companies, and others. The biopharmaceutical companies segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to the growing biopharmaceutical industry, rising investment in research and development, and rapid technological advancements in biopharmaceutical firms.
June 2019: Cygnus Technologies (US) launched mass spectrometry services for host cell protein impurity characterization. This new product launch will be helpful to identify and quantify impurities, which can impact the efficacy and stability of the therapy.
Host Cell Protein Testing Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America host cell protein testing market accounted for the largest market share in 2022. This is due to the increasing number of clinical trials, rising demand for innovative medicine for chronic diseases, and increasing research for gene and cell therapy products in the North American region. Companies such as Enzo Life Sciences, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abcam plc (UK), and Thermo Fisher Scientific Inc (US) are actively working on improving host cell protein testing and fulfilling the demands of customers. Thermo Fisher Scientific Inc (US) offers comprehensive research and Host Cell Protein Testing products, and in several research studies, the company has provided lucrative growth opportunities. Thus, the presence of key market players in the region fuels the growth of the host cell protein testing market in the region.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: HOST CELL PROTEIN TESTING MARKET SIZE, BY REGION 2023 & 2032 (USD Billion
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe host cell protein testing market accounts for the second-largest market share due to an increasing number of clinical trials in countries such as Germany, and France, highly adopted technologically advanced products in biopharmaceutical industries, and contract research organizations. further, Germany host cell protein testing market was attributed to hold the largest market share, and the France host cell protein testing market is expected to fastest-growing market in the European region.
The Asia-Pacific host cell protein testing market is expected to grow at a significant share from 2024 to 2032. This is due to the rising number of clinical trials with high intensity, increasing biopharmaceutical industries, and increasing investment in R&D in the Asia-Pacific region. Moreover, China host cell protein testing market is expected to hold the largest market share, and India host cell protein testing market is expected fastest-growing market in the Asia-Pacific region.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. The host cell protein testing market in the above-mentioned regions is likely to witness growth due to rising number of contract research organizations, high demand for monoclonal antibodies for infectious diseases, and increasing number of clinical trials in Brazil and Argentina. Moreover, lack of resources for host cell protein testing and dearth of skilled professionals to run tests are affecting the market's growth to some extent in these regions.
Host Cell Protein Testing Key Market Players & Competitive Insights
The Host Cell Protein Testing Market is characterized by the presence of many global, regional, and local vendors. Developments in the healthcare industry and growing research and development make the host cell protein testing market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Enzo Life Sciences, Inc (US) Bio-Rad Laboratories, Inc (US) Biogenes GmbH (Germany) Cisbio Bioassays (France) dominate the Host Cell Protein Testing Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global host cell protein testing industry to benefit clients and expand the host cell protein testing market sector is to manufacture locally to reduce operating costs.
Bio-Rad Laboratories, Inc. (US) provides the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process, and medical diagnostic labs obtain faster and better results. It provides instruments, software, consumables, reagents, and content in the areas of cell biology, gene expression, protein purification, and protein quantitation. The company also offers products for drug discovery & manufacture, food safety and environmental quality testing, and science education. Its products & solutions are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. The company operates through three business segments, namely, clinical diagnostics, life science, and others. The firm has a strong presence across North America, Europe, and Asia-Pacific. For instance, in March 2020, Bio-Rad Laboratories, Inc. (US) partnered with Assurance Scientific Laboratories, Birmingham, Alabama, (US) for the detection of COVID-19 samples using Bio-Rad’s CFX384 Touch Real-Time PCR Detection System. In addition, the company also partnered with other testing labs worldwide to support COVID-19 testing.
Also, Enzo Life Sciences, Inc (US) operates as a life sciences and biotechnology company. Enzo Life Sciences, Inc. is a wholly-owned subsidiary of Enzo Biochem, Inc. (US). It is engaging in the development, production, marketing, and sales of innovative life science research reagents across the globe. It offers a wide range of products, including proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits. The company offers its products for a wide range of applications for pharmaceutical industries, such as gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It has a strong distribution network across the globe. It has a strong presence number of countries, namely, France, Finland, Greece, Germany, Hungary, India, Indonesia, Iraq, Japan, Kuwait, Mexico, and New Zealand among others.
Key Companies in the Host Cell Protein Testing Market include
- Enzo Life Sciences, Inc (US)
- Bio-Rad Laboratories, Inc (US)
- Cisbio Bioassays (France)
- Rockland Immunochemicals, Inc (US)
- Agilent Technologies, Inc (US)
Host Cell Protein Testing Industry Developments
June 2021: Bio-Rad Laboratories, Inc (US) partnered with Seegene (South Korea) for the clinical development and commercialization of infectious disease molecular diagnostic products.
April 2020: Cytiva (US) collaborated with Avacta (UK) to develop and manufacture an Affimer-based point-of-care diagnostic test for detecting COVID-19 infection in large populations. The diagnostic assay will be transferred to Cytiva's unique point-of-care test strip platform and will work together to complete analytical and clinical validation of the test "as rapidly as possible.
August 2019: Cygnus Technologies, LLC (US) partnered with Bio-Techne Corporation (US) to develop a 3G Chinese hamster ovary host cell protein (CHO-HCP) assay. This partnership has introduced the co-developed third-generation CHO-HCP assay in the proprietary Simple Plex immunoassay cartridge for customers in North America and Europe.
Host Cell Protein Testing Market Segmentation
Host Cell Protein Testing Type Outlook
-
PCR-Based Assays
- Mass Spectrometry-Based Assays
- Liquid Chromatography–Mass Spectrometry (LC–MS)
- Tandem Mass Spectrometry (MS/MS)
Host Cell Protein Testing End User Outlook
- Contract Research Organizations
- Biopharmaceutical Companies
Host Cell Protein Testing Regional Outlook
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 1.31 billion |
| Market Size 2024 |
USD 1.38 billion |
| Market Size 2032 |
USD 2.17 billion |
| Compound Annual Growth Rate (CAGR) |
5.77% (2024-2032) |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Historical Data |
2019 to 2021 |
| Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type and End User |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea. |
| Key Companies Profiled |
Enzo Life Sciences, Inc (US), Bio-Rad Laboratories, Inc (US), Biogenes GmbH (Germany), Cisbio Bioassays (France), Abcam plc (UK), Thermo Fisher Scientific Inc (US), Cytiva (US), Cygnus Technologies, LLC (US), Rockland Immunochemicals, Inc (US), and Agilent Technologies, Inc (US) |
| Key Market Opportunities |
·      Growing Technological Advancements |
| Key Market Dynamics |
·      Growing R&D Activities·      Developments In the Biopharmaceutical Industry |
Host Cell Protein Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The Host Cell Protein Testing Market is anticipated to reach 2.17 billion at a CAGR of 5.77% during the forecast period of 2024-2032.
The US held over 87.46% share of the North America market for the host cell protein testing market during the forecast period of 2023-2032.
The host cell protein testing market is expected to grow at a 5.77% CAGR during the forecast period from 2024 to 2032.
The North American region market held the largest market share in the host cell protein testing market.
The key players include Enzo Life Sciences, Inc (US), Bio-Rad Laboratories, Inc (US), Biogenes GmbH (Germany), Cisbio Bioassays (France), Abcam plc (UK), Thermo Fisher Scientific Inc (US), Cytiva (US), Cygnus Technologies, LLC (US), Rockland Immunochemicals, Inc (US), and Agilent Technologies, Inc (US).
The ELISA-based assays segment was estimated to lead the host cell protein testing market.
The biopharmaceutical companies segment is attributed to having the largest market share based on end user
